Metabotropic glutamate receptors (mGluR1–8) are class C GPCRs — distinct from the fast ionotropic AMPA/NMDA/kainate channels. Three families with distinct G-protein coupling and synaptic localization: Group I (mGluR1, mGluR5) — Gq-coupled, postsynaptic, depolarizing — drives synaptic plasticity, LTD, Fragile-X synthesis; positive modulators trialed for cognition; negative modulators (mavoglurant — fragile X failed). Group II (mGluR2, mGluR3) — Gi/o-coupled, presynaptic autoreceptors — inhibit glutamate release; agonists (LY379268, LY2140023 — pomaglumetad) trialed for schizophrenia + anxiety; reverses 5-HT2A psychedelic effects (ketanserin/mGluR2 agonist crosstalk). Group III (mGluR4/6/7/8) — Gi/o, presynaptic + mGluR6 in retinal ON-bipolar cells; allosteric agonists trialed for Parkinson + anxiety. Distinct from iGluRs in being slower, modulatory, and pharmacologically tractable via allosteric sites (less off-target than the orthosteric glutamate site). Clinical relevance: ketamine's rapid antidepressant action involves disinhibition of glutamate release → AMPA → BDNF/mTOR (cross-link); group II agonists antagonize this (perampanel + LY379268). Riluzole (ALS) inhibits glutamate release in part through group I mGluR modulation. Fragile X is the prototypical mGluR-disorder (Bear hypothesis — excess mGluR5-LTD → phenotype; mGluR5 NAMs trialed but mostly failed). Cross-links: glutamate receptor pharmacology (parent), bdnf trkb neurotrophic (downstream of ketamine/glutamate disinhibition), serotonin 5ht2a psychedelic signaling (mGluR2 cross-talk).
Organ Systems
nervous
Pathway Steps
glutamate (synaptic spillover) → mGluR I (mGluR1, mGluR5) — postsynaptic Gq — via → PLC → IP3 + DAG; depolarizing; LTD. Group I mGluRs (mGluR1, mGluR5) sit postsynaptically and couple to Gq — so unlike the inhibitory groups they are generally excitatory, raising Ca²⁺ and enhancing NMDA-receptor function. mGluR5 is a major target in fragile X syndrome and is studied in anxiety and addiction.
glutamate (presynaptic autoreceptor) → mGluR II (mGluR2, mGluR3) — Gi/o — via → ↓cAMP + ↓Ca²⁺ channels → ↓glutamate release (negative feedback). Group II mGluRs (mGluR2, mGluR3) act largely as presynaptic autoreceptors coupled to Gi/o, suppressing further glutamate release — a negative-feedback brake on excitatory transmission. This is why mGluR2/3 agonists are anxiolytic and were trialed in schizophrenia and anxiety.
glutamate (presynaptic + retinal ON) → mGluR III (mGluR4/6/7/8) — Gi/o — via mGluR6 obligate for retinal ON-bipolar cells (CSNB1 disease). Group III mGluRs (mGluR4/6/7/8), also Gi/o-coupled, are mostly presynaptic; mGluR6 is the exception, mediating the sign-inverting glutamate response of retinal ON-bipolar cells. The group adds presynaptic inhibitory control and is a target in Parkinson’s (mGluR4) and retinal signaling.
mGluR2 activation → 5-HT2A psychedelic effect dampening — via mGluR2-5-HT2A heteromer or downstream antagonism — therapeutic for managing trip intensity. Group II mGluR2 cross-talks with the psychedelic target 5-HT2A: the two form receptor complexes, and mGluR2 activation dampens 5-HT2A-driven cortical excitation. This interaction is one reason mGluR2/3 agonists blunt psychedelic effects and links the glutamate and serotonin systems in cortex.
NMDA blockade (ketamine) → glutamate burst → AMPA → mGluR cross-talk — via paradoxical glutamate increase drives rapid antidepressant effect via BDNF/mTOR. Ketamine (an NMDA-receptor blocker) triggers a downstream glutamate burst that activates AMPA receptors and engages mGluR signaling, driving rapid synaptogenesis. This AMPA/mGluR cross-talk is part of the leading model for ketamine’s fast antidepressant action — convergent with the plasticity mechanism of psychedelics.